tideglusib   Click here for help

GtoPdb Ligand ID: 6929

Synonyms: NP-12 | NP031112
Compound class: Synthetic organic
Comment: Tideglusib is a small molecule non-ATP-competitive, irreversible glycogen synthase kinase 3 (GSK-3β) inhibitor [2] that has been investigated as a potential treatment for Alzheimer's disease and paralysis supranuclear palsy [4]. Low-dose tideglusib has been reported to induce natural reparative dentine formation, as a novel approach to treating tooth decay [5].

In vitro and in vivo, tideglusib (and analogues) has shown anti-staphylococcal activity, via inhibition of Staphylococcus aureus sortase A (SrtA; a virulence factor of Gram-positive pathogens) [6].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

tideglusib is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 71.72
Molecular weight 334.08
XLogP 4.07
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES O=c1sn(c(=O)n1Cc1ccccc1)c1cccc2c1cccc2
Isomeric SMILES O=c1sn(c(=O)n1Cc1ccccc1)c1cccc2c1cccc2
InChI InChI=1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2
InChI Key PMJIHLSCWIDGMD-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Phase 2a results for Alzheimer's disease reported [1]. Phase 2b completed as NCT01350362. Phase 2 trials vs. placebo in autism spectrum disorders (NCT02586935) and myotonic dystrophy (NCT02858908) are underway.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Potential mechanism of action in preventing inflammation and neurodegeneration is reviewed in [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01350362 Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease Patients Phase 2 Interventional Noscira SA
NCT02586935 Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders Phase 2 Interventional Anagnostou, Evdokia, M.D.
NCT02858908 Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Phase 2 Interventional AMO Pharma Limited